Pura Vida Investments LLC Boosted Stake in Merck & Co INC (MRK)

January 22, 2018 - By Clifton Ray

Investors sentiment decreased to 1.06 in 2017 Q3. Its down 0.01, from 1.07 in 2017Q2. It is negative, as 46 investors sold MRK shares while 619 reduced holdings. 106 funds opened positions while 598 raised stakes. 1.96 billion shares or 0.47% more from 1.95 billion shares in 2017Q2 were reported. Opus Point Ptnrs Management Limited Liability Corp has invested 4.81% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Chem Savings Bank accumulated 95,348 shares. Deroy Devereaux Private Invest Counsel Inc holds 1.8% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 250,192 shares. Fred Alger reported 0% in Merck & Co., Inc. (NYSE:MRK). Coho Prtn Ltd reported 2.18 million shares. Paloma Ptnrs Management Com has invested 0.06% in Merck & Co., Inc. (NYSE:MRK). Cullen Frost Bankers invested 0.46% of its portfolio in Merck & Co., Inc. (NYSE:MRK). Moreover, Walter Keenan Fincl Consulting Mi Adv has 1.1% invested in Merck & Co., Inc. (NYSE:MRK). Charter invested in 1.17% or 150,670 shares. Autus Asset Limited Liability Co owns 3,347 shares for 0.04% of their portfolio. Rowland Counsel Adv holds 1.35% of its portfolio in Merck & Co., Inc. (NYSE:MRK) for 49,532 shares. Bnp Paribas Asset Mngmt Sa has invested 0.79% in Merck & Co., Inc. (NYSE:MRK). Southeast Asset Advsrs reported 5,428 shares. Fil Ltd reported 1.79 million shares. Moreover, Wills Fincl has 1.15% invested in Merck & Co., Inc. (NYSE:MRK).

Pura Vida Investments Llc increased its stake in Merck & Co Inc (MRK) by 54.57% based on its latest 2017Q3 regulatory filing with the SEC. Pura Vida Investments Llc bought 54,570 shares as the company’s stock declined 2.46% while stock markets rallied. The institutional investor held 154,570 shares of the health care company at the end of 2017Q3, valued at $9.90B, up from 100,000 at the end of the previous reported quarter. Pura Vida Investments Llc who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $166.95 billion market cap company. The stock increased 0.25% or $0.15 during the last trading session, reaching $61.28. About 12.16 million shares traded. Merck & Co., Inc. (NYSE:MRK) has risen 16.86% since January 22, 2017 and is uptrending. It has outperformed by 0.16% the S&P500.

Pura Vida Investments Llc, which manages about $223.00 million and $199.58B US Long portfolio, decreased its stake in Nanostring Technologies Inc (Call) (NASDAQ:NSTG) by 298,206 shares to 100,000 shares, valued at $37.50 million in 2017Q3, according to the filing. It also reduced its holding in Array Biopharma Inc (Put) (NASDAQ:ARRY) by 113,089 shares in the quarter, leaving it with 152,500 shares, and cut its stake in Savara Inc.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: Nasdaq.com which released: “Merck & Co. Inc. (MRK) Is Up Sharply On Phase 3 Study Results” on January 09, 2018, also Investorplace.com with their article: “Merck & Co., Inc.’s Rally Could Burn Investors” published on January 19, 2018, Investorplace.com published: “After Irrational Fire Sale, It’s Time to Buy the Dip in Merck & Co., Inc. Stock” on January 09, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: Investorplace.com and their article: “Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success” published on January 16, 2018 as well as Investorplace.com‘s news article titled: “Merck & Co., Inc. Stock Could Still Soar Another 10% From Here” with publication date: January 18, 2018.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 23 analysts covering Merck & Co. Inc. (NYSE:MRK), 16 have Buy rating, 0 Sell and 7 Hold. Therefore 70% are positive. Merck & Co. Inc. has $7400 highest and $50 lowest target. $66.44’s average target is 8.42% above currents $61.28 stock price. Merck & Co. Inc. had 73 analyst reports since August 13, 2015 according to SRatingsIntel. Jefferies upgraded Merck & Co., Inc. (NYSE:MRK) on Tuesday, October 31 to “Hold” rating. As per Thursday, August 27, the company rating was maintained by Jefferies. The company was upgraded on Monday, October 30 by Citigroup. The firm has “Buy” rating given on Monday, June 12 by BMO Capital Markets. Jefferies maintained the stock with “Hold” rating in Thursday, July 14 report. Leerink Swann maintained the shares of MRK in report on Monday, October 30 with “Market Perform” rating. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Bank of America on Thursday, October 13. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Buy” rating by Piper Jaffray on Thursday, October 26. The rating was downgraded by SunTrust on Monday, October 30 to “Hold”. As per Thursday, October 12, the company rating was maintained by BMO Capital Markets.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: